

Литература к общему разделу: «САХАРНЫЙ ДИАБЕТ и КИШЕЧНЫЙ МИКРОБИОМ»

Литература к 1-му разделу о микробиоте и СД1

1. Mejia-Leon ME, Barca AM. Diet, microbiota and immune system in type 1 diabetes development and evolution. *Nutrients*. 2015;7(11):9171–84. [PubMed](#)
2. Pettitt DJ, Talton J, Dabelea D, Divers J, Imperatore G, Lawrence JM, et al. Prevalence of diabetes in US youth in 2009: the SEARCH for diabetes in youth study. *Diabetes Care*. 2014;37(2):402–8. [PubMed](#)
3. Notkins AL, Lernmark Å. Autoimmune type 1 diabetes: resolved and unresolved issues. *J Clin Invest*. 2001;108(9):1247–52. [PubMed](#)
4. Islam ST, Srinivasan S, Craig ME. Environmental determinants of type 1 diabetes: a role for overweight and insulin resistance. *J Paediatr Child Health*. 2014;50(11):874–9. [PubMed](#)
5. Alkanani AK, Hara N, Gottlieb PA, Ir D, Robertson CE, Wagner BD, et al. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. *Diabetes*. 2015;64(10):3510–20. [PubMed](#)
6. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell*. 2014;157(1):121–41. [PubMed](#)
7. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, et al. Succession of microbial consortia in the developing infant gut microbiome. *Proc Natl Acad Sci USA*. 2011;108(Suppl 1):4578–85. [PubMed](#)
8. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc Natl Acad Sci USA*. 2010;107(26):11971–5. [PubMed](#)
9. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. *PLoS Biol*. 2007;5(7):e177. [PubMed](#)
10. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. *Gastroenterology*. 2009;137(5):1716–24. [PubMed](#)
11. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. *Cell Host Microbe*. 2008;3(4):213–23. [PubMed](#)
12. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2006;444(7122):1027–31. [PubMed](#)
13. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med*. 2009;1(6):6ra14. [PubMed](#)
14. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? *Nat Rev Microbiol*. 2009;7(12):887–94. [PubMed](#)
15. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, et al. The long-term stability of the human gut microbiota. *Science*. 2013;341(6141):1237439. [PubMed](#)

16. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. *Nat Rev Endocrinol*. 2016;12(3):154–67. [PubMed](#)
17. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. *Cell*. 2014;158(4):705–21. [PubMed](#)
18. Qi C-J, Zhang Q, Yu M, Xu J-P, Zheng J, Wang T, et al. Imbalance of fecal microbiota at newly diagnosed type 1 diabetes in chinese children. *Chin Med J*. 2016;129(11):1298–304. [PubMed](#)
19. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. *BMJ*. 2018;361:k2179. [PubMed](#)
20. Parekh PJ, Balart LA, Johnson DA. The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease. *Clin Transl Gastroenterol*. 2015;6(6):e91. [PubMed](#)
21. Traversi D, Rabbone I, Ignaccolo MG, Carletto G, Racca I, Vallini C, et al. Gut microbiota diversity and T1DM onset: preliminary data of a case-control study. *Hum Microbiome J*. 2017;5:11–3. [Google Scholar](#)
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151(4):264–9. [PubMed](#)
23. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. *PLoS ONE*. 2011;6(10):e25792. [PubMed](#)
24. de Goffau MC, Fuentes S, van den Bogert B, Honkanen H, de Vos WM, Welling GW, et al. Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. *Diabetologia*. 2014;57(8):1569–77. [PubMed](#)
25. Maffei C, Martina A, Corradi M, Quarella S, Nori N, Torriani S, et al. Association between intestinal permeability and faecal microbiota composition in Italian children with beta cell autoimmunity at risk for type 1 diabetes. *Diabetes Metab Res Rev*. 2016;32(7):700–9. [PubMed](#)
26. Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. *BMC Med*. 2013;11(1):1–12. [Google Scholar](#)
27. Pellegrini S, Sordi V, Bolla AM, Saita D, Ferrarese R, Canducci F, et al. Duodenal mucosa of patients with type 1 diabetes shows distinctive inflammatory profile and microbiota. *J Clin Endocrinol Metab*. 2017;102(5):1468–77. [PubMed](#)
28. Soyucen E, Gulcan A, Aktuglu-Zeybek AC, Onal H, Kiykim E, Aydin A. Differences in the gut microbiota of healthy children and those with type 1 diabetes. *Pediatr Int*. 2014;56(3):336–43. [PubMed](#)
29. Stewart CJ, Nelson A, Campbell MD, Walker M, Stevenson EJ, Shaw JA, et al. Gut microbiota of type 1 diabetes patients with good glycaemic control and high physical fitness is similar to people without diabetes: an observational study. *Diabet Med*. 2017;34(1):127–34. [PubMed](#)
30. Mejia-Leon M, Petrosino J, Ajami N, Domínguez-Bello M, Calderon de la Barca A. HLA DQ/DR prevalence and microbiota disturbance in northwestern Mexican children with type 1 diabetes (1118.3). *FASEB J*. 2014;28(1_supplement):1118.3. [Google Scholar](#)
31. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, et al. Toward defining the autoimmune microbiome for type 1 diabetes. *ISME J*. 2011;5(1):82–91. [PubMed](#)
32. Huang Y, Li SC, Hu J, Ruan HB, Guo HM, Zhang HH, et al. Gut microbiota profiling in Han Chinese with type 1 diabetes. *Diabetes Res Clin Pract*. 2018;141:256–63. [PubMed](#)
33. Leiva-Gea I, Sanchez-Alcoholado L, Martin-Tejedor B, Castellano-Castillo D, Moreno-Indias I, Urda-Cardona A, et al. Gut microbiota differs in composition and functionality

- between children with type 1 diabetes and MODY2 and healthy control subjects: a case-control study. *Diabetes Care*. 2018;41(11):2385–95. [PubMed](#)
34. Higuchi BS, Rodrigues N, Gonzaga MI, Paiolo JCC, Stefanutto N, Omori WP, et al. Intestinal dysbiosis in autoimmune diabetes is correlated with poor glycemic control and increased interleukin-6: a pilot study. *Front Immunol*. 2018;9:1689. [PubMed](#)
 35. Salamon D, Sroka-Oleksiak A, Kapusta P, Szopa M, Mrozinska S, Ludwig-Slomczynska AH, et al. Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on nextgeneration sequencing of the 16S rRNA gene fragment. *Pol Arch Intern Med*. 2018;128(6):336–43. [PubMed](#)
 36. Cinek O, Kramna L, Mazankova K, Odeh R, Alassaf A, Ibekwe MU, et al. The bacteriome at the onset of type 1 diabetes: a study from four geographically distant African and Asian countries. *Diabetes Res Clin Pract*. 2018;144:51–62. [PubMed](#)
 37. Davis-Richardson AG, Ardisson AN, Dias R, Simell V, Leonard MT, Kempainen KM, et al. *Bacteroides dorei* dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. *Front Microbiol*. 2014;5:678. [PubMed](#)
 38. Endesfelder D, Engel M, Zu Castell W. Gut immunity and type 1 diabetes: a mélange of microbes, diet, and host interactions? *Curr Diabetes Rep*. 2016;16(7):60. [Google Scholar](#)
 39. Kostic AD, Gevers D, Siljander H, Vatanen T, Hyotylainen T, Hamalainen AM, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. *Cell Host Microbe*. 2015;17(2):260–73. [PubMed](#)
 40. Pinto E, Anselmo M, Calha M, Bottrill A, Duarte I, Andrew PW, et al. The intestinal proteome of diabetic and control children is enriched with different microbial and host proteins. *Microbiology*. 2017;163(2):161–74. [PubMed](#)
 41. Rozanova GN, Voevodin DA, Stenina MA, Kushnareva MV. Pathogenetic role of dysbacteriosis in the development of complications of type 1 diabetes mellitus in children. *Bull Exp Biol Med*. 2002;133(2):164–6. [PubMed](#)
 42. Gao X, Huynh B-T, Guillemot D, Glaser P, Opatowski L. Inference of significant microbial interactions from longitudinal metagenomics data. *Front Microbiol*. 2018;9:2319. [PubMed](#)
 43. Gavin PG, Mullaney JA, Loo D, Cao KL, Gottlieb PA, Hill MM, et al. Intestinal metaproteomics reveals host-microbiota interactions in subjects at risk for type 1 diabetes. *Diabetes Care*. 2018;41(10):2178–86. [PubMed](#)
 44. Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature*. 2018;562(7728):589–94. [PubMed](#)
 45. Stewart CJ, Ajami NJ, O'Brien JL, Hutchinson DS, Smith DP, Wong MC, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature*. 2018;562(7728):583–8. [PubMed](#)
 46. Endesfelder D, Zu Castell W, Ardisson A, Davis-Richardson AG, Achenbach P, Hagen M, et al. Compromised gut microbiota networks in children with anti-islet cell autoimmunity. *Diabetes*. 2014;63(6):2006–14. [PubMed](#)
 47. Cole DK, Bulek AM, Dolton G, Schauenberg AJ, Szomolay B, Rittase W, et al. Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. *J Clin Invest*. 2016;126(6):2191–204. [PubMed](#)
 48. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. *Aliment Pharmacol Ther*. 2008;27(2):104–19. [PubMed](#)
 49. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature*. 2013;504(7480):446–50. [PubMed](#)
 50. Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. *Nat Immunol*. 2013;14(7):676–84. [PubMed](#)
-

51. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol*. 2006;40(3):235–43. [PubMed](#)
52. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veecken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature*. 2013;504:451. [PubMed](#)
53. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Induction of colonic regulatory T cells by indigenous clostridium species. *Science*. 2011;331(6015):337–41. [PubMed](#)
54. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. *Annu Rev Immunol*. 2009;27:313–38. [PubMed](#)
55. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science*. 2013;341(6145):569–73. [PubMed](#)
56. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. *Nat Rev Microbiol*. 2011;10:66. [PubMed](#)
57. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. *J Allergy Clin Immunol*. 2005;115(6):1260–7. [PubMed](#)
58. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, et al. Factors influencing the composition of the intestinal microbiota in early infancy. *Pediatrics*. 2006;118(2):511–21. [PubMed](#)
59. Garcia E, Lopez R. *Streptococcus pneumoniae* type 3 encodes a protein highly similar to the human glutamate decarboxylase (GAD65). *FEMS Microbiol Lett*. 1995;133(1–2):113–8. [PubMed](#)

Литература ко 2-му разделу о микробиоте и СД2

1. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. *Science*. 2005;307(5717):1915–1920. doi:10.1126/science.1104816. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
2. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2006;444(7122):1027–1031. doi:10.1038/nature05414. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
3. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes*. 2007;56(7):1761–1772. doi:10.2337/db06-1491. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
4. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proc Natl Acad Sci USA*. 2007;104(3):979–984. doi:10.1073/pnas.0605374104. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
5. Adeshirlarijaney A, Zou J, Tran H, Chassaing B, Gewirtz AT. Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. *Am J Physiol Endocrinol Metab*. 2019. doi:10.1152/ajpendo.00245.2019. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]

6. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. *Diabetes*. 2002;51(8):2420–2425. doi:10.2337/diabetes.51.8.2420. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
7. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. *Diabetes*. 2002;51(7):2074–2081. doi:10.2337/diabetes.51.7.2074. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
8. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. *Open Forum Infect Dis*. 2015;2(1):ofv004. doi:10.1093/ofid/ofv004. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
9. Liou AP, Paziuk M, Luevano JM Jr., Machineni S, Turnbaugh PJ, Kaplan LM. Conserve d shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. *Sci Transl Med*. 2013;5(178):178ra41. doi:10.1126/scitranslmed.3005687. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
10. Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. *J Clin Endocrinol Metab*. 2004;89(11):5577–5582. doi:10.1210/jc.2004-0603. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
11. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. *J Clin Invest*. 2003;112(12):1785–1788. doi:10.1172/JCI20514. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
12. Vijay-
Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman S V, Knight R, Ley RE, Gewirtz AT, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science*. 2010;328(5975):228–231. doi:10.1126/science.1179721. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
13. Carvalho FA, Koren O, Goodrich JK, Johansson ME, Nalbantoglu I, Aitken JD, Su Y, Chassaing B, Walters W, González A, et al. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. *Cell Host Microbe*. 2012;12(2):139–152. doi:10.1016/j.chom.2012.07.004. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
14. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature*. 2012;490(7418):55–60. doi:10.1038/nature11450. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
15. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. *PLoS One*. 2010;5(2):e9085. doi:10.1371/journal.pone.0009085. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
16. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature*. 2013;498(7452):99–103. doi:10.1038/nature12198. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]

17. Yassour M, Lim MY, Yun HS, Tickle TL, Sung J, Song Y-M, Lee K, Franzosa EA, Morgan XC, Gevers D, et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. *Genome Med.* 2016;8(1):17. doi:10.1186/s13073-016-0271-6. [[Crossref](#)], [[PubMed](#)], [[Google Scholar](#)]
18. Yang Q, Lin SL, Kwok MK, Leung GM, Schooling CM. The roles of 27 genera of human gut microbiota in ischemic heart disease, Type 2 diabetes mellitus, and their risk factors: A Mendelian randomization study. *Am J Epidemiol.* 2018;187(9):1916–1922. doi:10.1093/aje/kwy096. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
19. Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L. Human gut microbiota changes reveal the progression of glucose intolerance. *PLoS One.* 2013;8(8):e71108. doi:10.1371/journal.pone.0071108. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
20. Chassaing B, Raja SM, Lewis JD, Srinivasan S, Gewirtz AT. Colonic microbiota encroachment correlates with dysglycemia in humans. *Cell Mol Gastroenterol Hepatol.* 2017;4(2):205–221. doi:10.1016/j.jcmgh.2017.04.001. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
21. Fuentes S, van Nood E, Tims S, Heikamp-de Jong I, Ter Braak CJ, Keller JJ, Zoetendal EG, de Vos WM. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent *Clostridium difficile* infection. *Isme J.* 2014;8(8):1621–1633. doi:10.1038/ismej.2014.13. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
22. Zou J, Chassaing B, Singh V, Pellizzon M, Ricci M, Fythe MD, Kumar MV, Gewirtz AT. Fiber-mediated nourishment of gut microbiota protects against diet-induced obesity by restoring IL-22-mediated colonic health. *Cell Host Microbe.* 2018;23(1):41–53 e4. doi:10.1016/j.chom.2017.11.003. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
23. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology.* 2012;143(4):913–6 e7. doi:10.1053/j.gastro.2012.06.031. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
24. de Groot P, Scheithauer T, Bakker GJ, Prodan A, Levin E, Khan MT, Herrema H, Ackermans M, Serlie MJM, de Brauw M, et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. *Gut.* pp.gutjnl-2019-318320. 2019. doi:10.1136/gutjnl-2019-318320 [[Crossref](#)], [[PubMed](#)], [[Google Scholar](#)]
25. Kootte RS, Levin E, Salojarvi J, Smits LP, Hartstra AV, Udayappan SD, Hermes G, Bouter KE, Koopen AM, Holst JJ, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. *Cell Metab.* 2017;26(4):611–9 e6. doi:10.1016/j.cmet.2017.09.008. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
26. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol.* 2014;11(8):506–514. doi:10.1038/nrgastro.2014.66. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]

27. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J, et al. Low counts of *Faecalibacterium prausnitzii* in colitis microbiota. *Inflamm Bowel Dis*. 2009;15(8):1183–1189. doi:10.1002/ibd.20903. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
28. Razmpoosh E, Javadi M, Ejtahed HS, Mirmiran P. Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. *Diabetes Metab Res Rev*. 2016;32(2):143–168. doi:10.1002/dmrr.2665. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
29. Tabuchi M, Ozaki M, Tamura A, Yamada N, Ishida T, Hosoda M, HOSONO A. Antidiabetic effect of *Lactobacillus* GG in streptozotocin-induced diabetic rats. *Biosci Biotechnol Biochem*. 2003;67(6):1421–1424. doi:10.1271/bbb.67.1421. [[Taylor & Francis Online](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
30. Yun SI, Park HO, Kang JH. Effect of *Lactobacillus gasseri* BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. *J Appl Microbiol*. 2009;107(5):1681–1686. doi:10.1111/jam.2009.107.issue-5. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
31. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Moller K, Svendsen KD, Jakobsen M, Pedersen BK. Effects of *Lactobacillus acidophilus* NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. *Br J Nutr*. 2010;104(12):1831–1838. doi:10.1017/S0007114510002874. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
32. Honda K, Moto M, Uchida N, He F, Hashizume N. Anti-diabetic effects of lactic acid bacteria in normal and type 2 diabetic mice. *J Clin Biochem Nutr*. 2012;51(2):96–101. doi:10.3164/jcbtn.11-07. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
33. Chen P, Zhang Q, Dang H, Liu X, Tian F, Zhao J, Chen Y, Zhang H, Chen W. Antidiabetic effect of *Lactobacillus casei* CCFM0412 on mice with type 2 diabetes induced by a high-fat diet and streptozotocin. *Nutrition*. 2014;30(9):1061–1068. doi:10.1016/j.nut.2014.03.022. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
34. Hariri M, Salehi R, Feizi A, Mirlohi M, Ghiasvand R, Habibi N. A randomized, double-blind, placebo-controlled, clinical trial on probiotic soy milk and soy milk: effects on epigenetics and oxidative stress in patients with type II diabetes. *Genes Nutr*. 2015;10(6):52. doi:10.1007/s12263-015-0503-1. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
35. Li X, Wang N, Yin B, Fang D, Jiang T, Fang S, Zhao J, Zhang H, Wang G, Chen W, et al. Effects of *Lactobacillus plantarum* CCFM0236 on hyperglycaemia and insulin resistance in high-fat and streptozotocin-induced type 2 diabetic mice. *J Appl Microbiol*. 2016;121(6):1727–1736. doi:10.1111/jam.2016.121.issue-6. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
36. Yin YN, Yu QF, Fu N, Liu XW, Lu FG. Effects of four Bifidobacteria on obesity in high-fat diet induced rats. *World J Gastroenterol*. 2010;16(27):3394–3401. doi:10.3748/wjg.v16.i27.3394. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
37. Stenman LK, Waget A, Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic *Bifidobacterium animalis* spp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. *Benef Microbes*. 2014;5(4):437–445. doi:10.3920/BM2014.0014. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
38. Hampe CS, Roth CL. Probiotic strains and mechanistic insights for the treatment of type 2 diabetes. *Endocrine*. 2017;58(2):207–227. doi:10.1007/s12020-017-1433-z. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]

39. Han MM, Sun JF, Su XH, Peng YF, Goyal H, Wu CH, Zhu XY, Li L. Probiotics improve glucose and lipid metabolism in pregnant women: a meta-analysis. *Ann Transl Med.* 2019;7(5):99. doi:10.21037/atm.2019.01.61. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
40. Gerard C, Vidal H. Impact of gut microbiota on host glycemic control. *Front Endocrinol (Lausanne).* 2019;10:29. doi:10.3389/fendo.2019.00029. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
41. Remely M, Hippe B, Zanner J, Aumueller E, Brath H, Haslberger AG. Gut microbiota of obese, Type 2 diabetic individuals is enriched in *Faecalibacterium prausnitzii*, *Akkermansia muciniphila* and *Peptostreptococcus anaerobius* after weight loss. *Endocr Metab Immune Disord Drug Targets.* 2016;16(2):99–106. doi:10.2174/1871530316666160831093813. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
42. Dao MC, Everard A, Aron-Wisniewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Høyle L, et al. *Akkermansia muciniphila* and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut.* 2016;65(3):426–436. doi:10.1136/gutjnl-2014-308778. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
43. Bonora E, Cigolini M, Bosello O, Zancanaro C, Capretti L, Zavaroni I, Coscelli C, Butturini U. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. *Curr Med Res Opin.* 1984;9(1):47–51. doi:10.1185/03007998409109558. [[Taylor & Francis Online](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
44. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Krogh Pedersen H, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature.* 2015;528(7581):262–266. doi:10.1038/nature15766. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
45. Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, et al. Metformin alters the gut microbiome of individuals with treatment-naïve type 2 diabetes, contributing to the therapeutic effects of the drug. *Nat Med.* 2017;23(7):850–858. doi:10.1038/nm.4345. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
46. Ejtahed HS, Tito RY, Siadat SD, Hasani-Ranjbar S, Hoseini-Tavassol Z, Rymenans L, Verbeke K, Soroush AR, Raes J, Larijani B. Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial. *Eur J Endocrinol.* 2018;180:165–176. [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
47. Rosario D, Benfeitas R, Bidkhorji G, Zhang C, Uhlen M, Shoaie S, Mardinoglu A. Understanding the representative gut microbiota dysbiosis in metformin-treated Type 2 diabetes patients using genome-scale metabolic modeling. *Front Physiol.* 2018;9:775. doi:10.3389/fphys.2018.00775. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
48. Lee H, Ko G. Effect of metformin on metabolic improvement and gut microbiota. *Appl Environ Microbiol.* 2014;80(19):5935–5943. doi:10.1128/AEM.01357-14. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
49. de la Cuesta-zuluaga J, Mueller NT, Corrales-Agudelo V, Velasquez-Mejia EP, Carmona JA, Abad JM, Escobar JS. Metformin is associated with higher relative abundance of mucin-degrading *Akkermansia muciniphila* and several short-chain fatty acid-producing microbiota in the gut. *Diabetes Care.* 2017;40(1):54–62. doi:10.2337/dc16-1324. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]

50. Ejtahed HS, Soroush AR, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut microbiota as a target in the pathogenesis of metabolic disorders: a new approach to novel therapeutic agents. *Horm Metab Res.* 2016;48:349–358. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
51. Vallianou NG, Stratigou T, Tsagarakis S. Metformin and gut microbiota: their interactions and their impact on diabetes. *Hormones (Athens).* 2019;18(2):141–144. doi:10.1007/s42000-019-00093-w. [[Crossref](#)], [[PubMed](#)], [[Google Scholar](#)]
52. Su B, Liu H, Li J, Sunli Y, Liu B, Liu D, Zhang P, Meng X. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. *J Diabetes.* 2015;7(5):729–739. doi:10.1111/1753-0407.12232. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
53. Zhang X, Fang Z, Zhang C, Xia H, Jie Z, Han X, Chen Y, Ji L. Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial. *Diabetes Ther.* 2017;8(2):293–307. doi:10.1007/s13300-017-0226-y. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
54. Moreira GV, Azevedo FF, Ribeiro LM, Santos A, Guadagnini D, Gama P, Liberti EA, Saad M, Carvalho C. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. *J Nutr Biochem.* 2018;62:143–154. doi:10.1016/j.jnutbio.2018.07.009. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
55. Zhang Q, Xiao X, Zheng J, Li M, Yu M, Ping F, Wang T, Wang X. Featured article: structure moderation of gut microbiota in liraglutide-treated diabetic male rats. *Exp Biol Med (Maywood).* 2018;243(1):34–44. doi:10.1177/1535370217743765. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
56. Wang L, Li P, Tang Z, Yan X, Feng B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. *Sci Rep.* 2016;6:33251. doi:10.1038/srep33251. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
57. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. *J Biol Chem.* 2006;281(13):8748–8755. doi:10.1074/jbc.M505649200. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
58. Yan X, Feng B, Li P, Tang Z, Wang L. Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study. *J Diabetes Res.* 2016;2016:2093171. doi:10.1155/2016/2093171. [[Crossref](#)], [[PubMed](#)], [[Google Scholar](#)]
59. Zhang Q, Xiao X, Li M, Yu M, Ping F, Zheng J, Wang T, Wang X. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. *PLoS One.* 2017;12(10):e0184735. doi:10.1371/journal.pone.0184735. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
60. Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. *Med Sci Monit.* 2011;17(7):RA164–7. doi:10.12659/MSM.881842. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
61. Anhe FF, Roy D, Pilon G, Dudonne S, Matamoros S, Varin TV, Garofalo C, Moine Q, Desjardins Y, Levy E, et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with

- increased *Akkermansia* spp. population in the gut microbiota of mice. *Gut*. 2015;64(6):872–883. doi:10.1136/gutjnl-2014-307142. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
62. Song H, Chu Q, Yan F, Yang Y, Han W, Zheng X. Red pitaya betacyanins protects from diet-induced obesity, liver steatosis and insulin resistance in association with modulation of gut microbiota in mice. *J Gastroenterol Hepatol*. 2016;31(8):1462–1469. doi:10.1111/jgh.2016.31.issue-8. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
63. Abbasi Oshaghi E, Goodarzi MT, Higgins V, Adeli K. Role of resveratrol in the management of insulin resistance and related conditions: mechanism of action. *Crit Rev Clin Lab Sci*. 2017;54(4):267–293. doi:10.1080/10408363.2017.1343274. [[Taylor & Francis Online](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
64. Huang G, Xu J, Lefever DE, Glenn TC, Nagy T, Guo TL. Genistein prevention of hyperglycemia and improvement of glucose tolerance in adult non-obese diabetic mice are associated with alterations of gut microbiome and immune homeostasis. *Toxicol Appl Pharmacol*. 2017;332:138–148. doi:10.1016/j.taap.2017.04.009. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
65. Song JX, Ren H, Gao YF, Lee CY, Li SF, Zhang F, Li L, Chen H. Dietary capsaicin improves glucose homeostasis and alters the gut microbiota in obese diabetic ob/ob mice. *Front Physiol*. 2017;8:602. doi:10.3389/fphys.2017.00602. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
66. Shtriker MG, Hahn M, Taieb E, Nyska A, Moallem U, Tirosh O, Madar Z. Fenugreek galactomannan and citrus pectin improve several parameters associated with glucose metabolism and modulate gut microbiota in mice. *Nutrition*. 2018;46:134–42 e3. doi:10.1016/j.nut.2017.07.012. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
67. Zhai B, Zhang C, Sheng Y, Zhao C, He X, Xu W, Huang K, Luo Y. Hypoglycemic and hypolipidemic effect of S-allyl-cysteine sulfoxide (alliin) in DIO mice. *Sci Rep*. 2018;8(1):3527. doi:10.1038/s41598-018-21421-x. [[Crossref](#)], [[PubMed](#)], [[Google Scholar](#)]
68. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, Li M, Zhang C, Zhang Z, Zhang Y, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. *PLoS One*. 2012;7(8):e42529. doi:10.1371/journal.pone.0042529. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
69. Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, Zhang X, Zhao L. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. *Sci Rep*. 2015;5:14405. doi:10.1038/srep14405. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
70. Zhang B, Yue R, Chen Y, Yang M, Huang X, Shui J, Peng Y, Chin J. Gut microbiota, a potential new target for Chinese herbal medicines in treating diabetes mellitus. *Evid Based Complement Alternat Med*. 2019;2019:2634898. [[PubMed](#)], [[Google Scholar](#)]
71. Sheng Y, Zheng S, Ma T, Zhang C, Ou X, He X, Xu W, Huang K. Mulberry leaf alleviates streptozotocin-induced diabetic rats by attenuating NEFA signaling and modulating intestinal microflora. *Sci Rep*. 2017;7(1):12041. doi:10.1038/s41598-017-12245-2. [[Crossref](#)], [[PubMed](#)], [[Google Scholar](#)]
72. Xie Y, Xiao M, Ni Y, Jiang S, Feng G, Sang S, Du G. *Alpinia oxyphylla* Miq. extract prevents diabetes in mice by modulating gut microbiota. *J Diabetes Res*. 2018;2018:4230590. doi:10.1155/2018/4230590. [[Crossref](#)], [[PubMed](#)], [[Google Scholar](#)]

73. Gao K, Yang R, Zhang J, Wang Z, Jia C, Zhang F, Li S, Wang J, Murtaza G, Xie H, et al. Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology. *Pharmacol Res.* 2018;130:93–109. doi:10.1016/j.phrs.2018.01.011. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
74. Li XW, Chen HP, He YY, Chen WL, Chen JW, Gao L, Hu H-Y, Wang J. Effects of rich-polyphenols extract of *Dendrobium loddigesii* on anti-diabetic, anti-inflammatory, anti-oxidant, and gut microbiota modulation in db/db mice. *Molecules.* 2018;23(12):3245. doi:10.3390/molecules23123245. [[Crossref](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
75. Anhe FF, Nachbar RT, Varin TV, Vilela V, Dudonne S, Pilon G, Fournier M, Lecours MA, Desjardins Y, Roy D, et al. A polyphenol-rich cranberry extract reverses insulin resistance and hepatic steatosis independently of body weight loss. *Mol Metab.* 2017;6(12):1563–1573. doi:10.1016/j.molmet.2017.10.003. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
76. Yan X, Yang C, Lin G, Chen Y, Miao S, Liu B, Zhao C. Antidiabetic potential of green seaweed *Enteromorpha prolifera* flavonoids regulating insulin signaling pathway and gut microbiota in Type 2 diabetic mice. *J Food Sci.* 2019;84(1):165–173. doi:10.1111/1750-3841.14415. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
77. Lin R, He X, Chen H, He Q, Yao Z, Li Y, Yang H, Simpson S. Oil tea improves glucose and lipid levels and alters gut microbiota in type 2 diabetic mice. *Nutr Res.* 2018;57:67–77. doi:10.1016/j.nutres.2018.05.004. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
78. Van Hul M, Geurts L, Plovier H, Druart C, Everard A, Stahlman M, Rhimi M, Chira K, Teiss edre P-L, Delzenne NM, et al. Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier. *Am J Physiol Endocrinol Metab.* 2018;314(4):E334–E52. doi:10.1152/ajpendo.00107.2017. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
79. Wang JH, Bose S, Shin NR, Chin YW, Choi YH, Kim H, Lin R, He X, Chen H, He Q, et al. Pharmaceutical impact of *Houttuynia cordata* and metformin combination on high-fat-diet-induced metabolic disorders: link to intestinal microbiota and metabolic endotoxemia. *Front Endocrinol (Lausanne).* 2018;9:620. doi:10.3389/fendo.2018.00620. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
80. Makki K, Deehan EC, Walter J, Backhed F. The impact of dietary fiber on gut microbiota in host health and disease. *Cell Host Microbe.* 2018;23(6):705–715. doi:10.1016/j.chom.2018.05.012. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
81. Cani PD. Gut microbiota and obesity: lessons from the microbiome. *Brief Funct Genomics.* 2013;12(4):381–387. doi:10.1093/bfpg/elt014. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]
82. Cani PD, de Vos WM. Next-generation beneficial microbes: the case of *Akkermansia muciniphila*. *Front Microbiol.* 2017;8:1765. doi:10.3389/fmicb.2017.01765. [[Crossref](#)], [[PubMed](#)], [[Web of Science ®](#)], [[Google Scholar](#)]